New drug trial offers hope for Tough-to-Treat amyloidosis
NCT ID NCT06649695
Summary
This study is testing an investigational drug called teclistamab in people with AL amyloidosis who have already tried other treatments. The goal is to see if teclistamab can effectively reduce the harmful proteins produced by the disease. Researchers will measure how many participants achieve a deep reduction or complete disappearance of these proteins in their blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Limoges
NOT_YET_RECRUITINGLimoges, France
Contact
-
Fondazione I.R.C.C.S Policlinico "San Matteo"
NOT_YET_RECRUITINGPavia, Italy
Contact
-
General Hospital of Athens "Alexandra"
RECRUITINGAthens, Greece
Contact
-
Paris St Louis
NOT_YET_RECRUITINGParis, France
Contact
-
South Australia Health
NOT_YET_RECRUITINGAdelaide, Australia
Contact
-
UMC Utrecht
RECRUITINGUtrecht, Netherlands
Contact
-
University Hospital Essen
RECRUITINGEssen, Germany
Contact
-
University Hospital Heidelberg
RECRUITINGHeidelberg, Germany
Contact
-
University Hospital Würzburg
NOT_YET_RECRUITINGWürzburg, Germany
Contact
-
Westmead Hospital
RECRUITINGSydney, Australia
Contact
Conditions
Explore the condition pages connected to this study.